Related Experiment Video
Updated: May 14, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Medical therapy of coronary artery disease after percutaneous intervention
1Clinic for Cardiology, Department of Internal Medicine, Triemli Hospital, Zurich, Switzerland.
Insights
Second-generation drug-eluting stents (DES) improve outcomes after percutaneous coronary intervention (PCI). Newer antiplatelet agents like prasugrel and ticagrelor offer superior protection against stent thrombosis and ischemic events compared to clopidogrel.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Medical therapy post-percutaneous coronary intervention (PCI) is crucial for preventing coronary disease progression and complications.
- Key complications following coronary stenting include stent thrombosis and restenosis.
- Drug-eluting stents (DES) are the primary method for preventing in-stent restenosis through localized drug delivery.
Purpose of the Study:
- To evaluate the advancements in second-generation DES.
- To assess the efficacy and safety of newer antiplatelet agents in preventing stent thrombosis and ischemic events after PCI.
Main Methods:
- Review of innovations in drug coating, polymer drug-delivery systems, and stent design for second-generation DES.
- Analysis of dual anti-platelet therapy regimens, including acetylsalicylic acid and P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor).
Main Results:
- Second-generation DES demonstrate improved efficacy and safety profiles.
- Prasugrel and ticagrelor provide more potent and consistent platelet inhibition than clopidogrel.
- Newer antiplatelet agents are more effective in preventing ischemic events in acute coronary syndrome patients post-PCI.
Conclusions:
- Advancements in DES technology have enhanced restenosis prevention.
- Newer P2Y12 inhibitors represent a significant improvement over clopidogrel for preventing stent thrombosis and ischemic complications.
- Optimized medical therapy, including advanced DES and potent antiplatelet agents, is essential for improving outcomes after PCI.
Abstract:
Medical therapy following percutaneous coronary intervention aims at preventing first, coronary disease progression and its clinical manifestations, and finally, the two main complications of coronary stenting, stent thrombosis and restenosis. Prevention of in-stent restenosis is restricted to local drug delivery in the form of drug eluting stents (DES). Second generation DES have improved their efficacy and safety profile by innovations in drug coating, the polymer drug-delivery system and stent design. The mainstay of stent thrombosis prevention remains dual anti-platelet therapy with acetylsalicylic acid and a platelet ADP-receptor blocker, traditionally clopidogrel. Two new drugs, prasugrel and ticagrelor, provide faster, greater, and more consistent platelet inhibition than clopidogrel, and have been shown to be more efficacious in preventing ischemic events after PCI in acute coronary syndrome patients.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Cardiomyopathy V: Interprofessional Care
